Regencell Bioscience (RGC) has had the highest return since January 1, 2025 by a US stock with a market cap of $20,111+, returning 9,331.1%.
| ASSET | % RETURN |
|---|---|
Regencell Bioscience (RGC) | 9,331.14% |
QMMM Holdings Limited Ordinary Shares (QMMM) | 9,155.81% |
Diginex Limited Ordinary Shares (DGNX) | 1,877.46% |
ZimVie (ZIMV) | 1,531.21% |
Abivax SA American Depositary Shares (ABVX) | 1,424.72% |
Oncology Institute (TOI) | 1,197.39% |
DeFi Development (DFDV) | 935.82% |
Abits (ABTS) | 903.92% |
Zepp Health (ZEPP) | 822.69% |
Newegg Commerce (NEGG) | 801.13% |
Rich Sparkle Holdings Limited Ordinary Shares (ANPA) | 733.33% |
Nova Lifestyle I (NVFY) | 713.92% |
Cidara Therapeutics (CDTX) | 703.06% |
Relmada Therapeutics (RLMD) | 661.37% |
Sandisk (SNDK) | 624.93% |
FiEE (FIEE) | 624.77% |
Palvella Therapeutics (PVLA) | 621.1% |
Celcuity LLC (CELC) | 601.06% |
Nanobiotix (NBTX) | 568.81% |
Global Interactive Technologies (GITS) | 528.63% |
Better Home & Finance (BETR) | 514.42% |
Lizhi (SOGP) | 510.47% |
Galecto (GLTO) | 461.3% |
Dominari (DOMH) | 448.88% |
ThredUp (TDUP) | 419.44% |
